Sumitomo Pharma announces availability of Orgovyx (relugolix) in Canada, the first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer

12 March 2024 - Sumitomo Pharma announced today that Orgovyx (relugolix), an oral gonadotropin-releasing hormone receptor antagonist, is now available for ...

Read more →

AbbVie's Vyalev (foslevodopa/foscarbidopa solution) available for the treatment of advanced Parkinson's disease in Canada

8 February 2024 - In clinical trials, patients taking Vyalev achieved the primary endpoint of a reduction in motor fluctuations ...

Read more →

Organon Canada announces availability of a high concentration, citrate free formulation of Hadlima, a biosimilar to Humira

26 October 2023 - Hadlima 40 mg/0.4 mL offers a higher concentration compared to Hadlima 40 mg/0.8 mL. ...

Read more →

Medison Pharma announces public formulary listing of Qinlock (ripretinib) in Canadian provinces: Ontario and Quebec for advanced gastro-intestinal stromal tumour treatment

29 September 2023 - Medison Pharma is pleased to announce the public formulary listing of Qinlock in Canadian provinces: Ontario ...

Read more →

Jazz Pharmaceuticals enters into letter of intent with the pan-Canadian Pharmaceutical Alliance for Rylaze, helping address the unmet need of acute lymphoblastic leukaemia and lymphoblastic lymphoma patients across Canada

2 August 2023 - Jazz Pharmaceuticals today announced that the Company has entered into a letter of intent with the pan-Canadian ...

Read more →

Sandoz Canada expands its generics portfolio with three new products

5 July 2022 - Generic medicines like these three products help make effective medicine more affordable and accessible for Canadians and ...

Read more →

Viatris and Biocon Biologics launch Abevmy (bevacizumab), their third oncology siosimilar, in Canada

19 May 2022 - Viatris and Biocon Biologics announced today that Abevmy (bevacizumab) is now available in Canada.  ...

Read more →

Health Canada releases What We Heard Report from the public engagement on the National Strategy for Drugs for Rare Diseases

26 July 2021 - Too many Canadians are struggling to access the drugs they need, especially if they have a rare ...

Read more →

Cystic fibrosis life-altering drug nearing patient access across the country: Health Canada

20 June 2021 - For the cystic fibrosis community, persistence and constant belief are paying off. ...

Read more →

Cystic Fibrosis Canada says 'life-changing' drug coming to Canada, but approval months away

11 November 2020 - The drug's manufacturer says it's moving forward with its cystic fibrosis medicines in Canada. ...

Read more →

Manufacturer moves to bring 'life-changing' cystic fibrosis drugs to Canada

10 November 2020 - A pharmaceutical company says it's taking steps to bring cystic fibrosis drugs to Canada in a ...

Read more →

Cystic fibrosis drug could reduce severe disease, deaths if made available to Canadians

25 August 2020 - Talia D’Alessio has been living with cystic fibrosis since she was nine months old. ...

Read more →

Alberta may circumvent Health Canada to gain access to COVID-19 tests and drugs, premier says

13 April 2020 - Dr. Theresa Tam says Health Canada has 'significant concerns' about the quality of some tests. ...

Read more →

Does an orphan drug policy make a difference in access? A comparison of Canada and Australia.

2 January 2020 - Canada has been discussing whether to implement an orphan drug policy for more than 25 years. Recently, ...

Read more →

Novartis completes certification of initial sites in Ontario for first approved Canadian CAR-T therapy, Kymriah (tisagenlecleucel)

12 December 2019 - Ontario government to reimburse Kymriah therapy for certain patients with life-threatening cancers who are in critical need. ...

Read more →